Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7060641rdf:typepubmed:Citationlld:pubmed
pubmed-article:7060641lifeskim:mentionsumls-concept:C0034798lld:lifeskim
pubmed-article:7060641lifeskim:mentionsumls-concept:C0016367lld:lifeskim
pubmed-article:7060641lifeskim:mentionsumls-concept:C0332206lld:lifeskim
pubmed-article:7060641lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:7060641lifeskim:mentionsumls-concept:C1527240lld:lifeskim
pubmed-article:7060641pubmed:issue4lld:pubmed
pubmed-article:7060641pubmed:dateCreated1982-5-21lld:pubmed
pubmed-article:7060641pubmed:abstractTextFlupenthixyl chloride (FPT-Cl), a derivative of the dopamine (DA) receptor antagonist and neuroleptic alpha-flupenthixol possessing a chloroethyl side chain, has been prepared and evaluated for use in vivo in affinity labeling of DA receptors. Binding of [3H]spiperone to rat striatal DA receptors was markedly altered up to 12 h after intraventricular injection of FPT-Cl as compared with controls, while Scatchard plots of [3H]spiperone binding obtained on rat striatal homogenates 24 and 48 h after injection of FPT-Cl had values of Bmax significantly lower than in controls. The results suggest that the administration of FPT-Cl leads to irreversible and possibly covalent blockade of a portion of the spiperone binding sites in rat striatum. A second population of receptors appears to be blocked reversibly and presumably noncovalently by FPT-Cl, and these spiperone binding sites are partially reactivated in vivo after 48 h.lld:pubmed
pubmed-article:7060641pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7060641pubmed:languageenglld:pubmed
pubmed-article:7060641pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7060641pubmed:citationSubsetIMlld:pubmed
pubmed-article:7060641pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7060641pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7060641pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7060641pubmed:statusMEDLINElld:pubmed
pubmed-article:7060641pubmed:monthFeblld:pubmed
pubmed-article:7060641pubmed:issn0014-2999lld:pubmed
pubmed-article:7060641pubmed:authorpubmed-author:MurphyR BRBlld:pubmed
pubmed-article:7060641pubmed:authorpubmed-author:SchusterD IDIlld:pubmed
pubmed-article:7060641pubmed:authorpubmed-author:HoldenW LWLlld:pubmed
pubmed-article:7060641pubmed:authorpubmed-author:NarulaA PAPlld:pubmed
pubmed-article:7060641pubmed:issnTypePrintlld:pubmed
pubmed-article:7060641pubmed:day5lld:pubmed
pubmed-article:7060641pubmed:volume77lld:pubmed
pubmed-article:7060641pubmed:ownerNLMlld:pubmed
pubmed-article:7060641pubmed:authorsCompleteYlld:pubmed
pubmed-article:7060641pubmed:pagination313-6lld:pubmed
pubmed-article:7060641pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:7060641pubmed:meshHeadingpubmed-meshheading:7060641-...lld:pubmed
pubmed-article:7060641pubmed:meshHeadingpubmed-meshheading:7060641-...lld:pubmed
pubmed-article:7060641pubmed:meshHeadingpubmed-meshheading:7060641-...lld:pubmed
pubmed-article:7060641pubmed:meshHeadingpubmed-meshheading:7060641-...lld:pubmed
pubmed-article:7060641pubmed:meshHeadingpubmed-meshheading:7060641-...lld:pubmed
pubmed-article:7060641pubmed:meshHeadingpubmed-meshheading:7060641-...lld:pubmed
pubmed-article:7060641pubmed:meshHeadingpubmed-meshheading:7060641-...lld:pubmed
pubmed-article:7060641pubmed:meshHeadingpubmed-meshheading:7060641-...lld:pubmed
pubmed-article:7060641pubmed:year1982lld:pubmed
pubmed-article:7060641pubmed:articleTitleIrreversible blockade of striatal dopamine receptors in vivo by a derivative of alpha-flupenthixol.lld:pubmed
pubmed-article:7060641pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7060641pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed